Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05397119 · ClinicalTrials.gov registry record · Phase 1
A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Pandemic Flu Vaccine in Healthy Adults
A Phase 1 study of Influenza, Pandemic, sponsored by BlueWillow Biologics.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT05397119: Completed Phase 1 study of Influenza, Pandemic, sponsored by BlueWillow Biologics.
NCT05397119 is a Phase 1 study of Influenza, Pandemic that has completed, run by BlueWillow Biologics. The registered enrollment target is 40 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05397119, a Phase 1 study of Influenza, Pandemic, has completed, sponsored by BlueWillow Biologics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this clinical trial is to evaluate the safety and immunogenicity of BW-1014. BW-1014 is a nanoemulsion (NE) adjuvanted recombinant Hemagglutinin 5 (rH5) that would protect against pandemic flu. The study will be conducted in 40 healthy adults volunteers, age 18 - 45, in one center in the United States. The study will compare 3 different dose levels of rH5 (25µg, 50µg and 100µg rH5 in 20% NE adjuvant using a pipette dropper with rH5 control (100µg without NE adjuvant) and placebo control (saline). The investigational product will be administered in 2 doses intranasally (IN). This will be followed 6 months later with a licensed H5N1 IIV IM vaccine. In addition to safety outcome, homologous and heterologous immunological outcomes will be tested in nasal wash, serum, and blood cells.
Primary Outcome
Local and systemic reactions will be assessed in the clinic within 1 hour of intranasal BW-1014, positive control, and placebo administration, including visual assessment of nasal passages
Conditions Studied
Interventions
- BIOLOGICAL BW-1014: 25 µg rH5 in 20% NE - pipette - IN
- BIOLOGICAL BW-1014: 50 µg rH5 in 20% NE - pipette - IN
- BIOLOGICAL BW-1014: 100 µg rH5 in 20% NE - pipette - IN
- BIOLOGICAL rH5 (100 µg) control - pipette - IN
- BIOLOGICAL Saline (Placebo) - pipette - IN
Study Locations (1)
Maryland
- Center for Vaccine Development and Global Health, University of Maryland School of Medicine - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2022-07-07 |
| Est. Completion | 2023-10-12 |
| Phase | Phase 1 |
What the finished NCT05397119 record still lists
NCT05397119 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% lower).
The record links to 1 condition, with Influenza, Pandemic appearing as the primary indexed condition, and to 5 interventions - of which BW-1014: 25 µg rH5 in 20% NE - pipette - IN is the first listed.
NCT05397119 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT05397119 about?
NCT05397119 is a clinical study titled "A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Pandemic Flu Vaccine in Healthy Adults". The purpose of this clinical trial is to evaluate the safety and immunogenicity of BW-1014. BW-1014 is a nanoemulsion (NE) adjuvanted recombinant Hemagglutinin 5 (rH5) that would protect against pandemic flu. The study will be conducted in 40 healthy adults volunteers, age 18 - 45, in one center i...
What is the current status of trial NCT05397119?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2022-07-07. Estimated completion is 2023-10-12.
What conditions does trial NCT05397119 study?
This clinical trial studies the following conditions: Influenza, Pandemic.
What interventions are being tested in trial NCT05397119?
The interventions under investigation include: BW-1014: 25 µg rH5 in 20% NE - pipette - IN (BIOLOGICAL), BW-1014: 50 µg rH5 in 20% NE - pipette - IN (BIOLOGICAL), BW-1014: 100 µg rH5 in 20% NE - pipette - IN (BIOLOGICAL), rH5 (100 µg) control - pipette - IN (BIOLOGICAL), Saline (Placebo) - pipette - IN (BIOLOGICAL).
Who is sponsoring clinical trial NCT05397119?
This trial is sponsored by BlueWillow Biologics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05397119 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Influenza, Pandemic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05397119's enrollment target sits among peer trials
40 1130th of 2000 higher than 810 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI